Business Context and Reporting Period
This Form 8-K Current Report from CareDx, Inc. (CDNA) covers events occurring on September 30, 2024, with the report filed on October 4, 2024. The filing primarily addresses the departure of a senior executive and the associated compensatory arrangements.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It details specific one-time compensation costs related to an executive separation:
- Severance Bonus: $517,920 (200% of target bonus).
- Retention Bonus: $300,000 (unpaid portion).
- Consulting Fee: $107,901 (aggregate fee for a six-month term).
- Other Benefits: Six months of base salary continuation and COBRA premium reimbursement.
Material Changes
The material change reported is the termination of Alexander Johnson, President of Patient and Testing Services, effective September 13, 2024. The separation was treated as a termination without "cause." This event triggers the payment of the severance and bonus amounts listed above, representing a discrete cash outflow not present in prior comparable periods.
Outlook, Risks, and Unusual Items
Management Commentary and Transition: The Company entered into a consulting agreement with Mr. Johnson, effective retroactively to September 14, 2024, to ensure a smooth transition of duties. He will provide up to 40 hours of service per month for six months.
Risks and Contingencies: The separation agreement includes a mutual non-disparagement provision and a 12-month non-solicitation clause. The consulting agreement is subject to termination for "good cause" or upon Mr. Johnson's revocation of the release, which would impact the pro-rated payment of the consulting fee and the vesting of equity awards.
Investor Verification Checklist
- Verify the total cash impact of the separation package ($817,920 in immediate bonuses plus salary continuation and consulting fees).
- Confirm the timeline for the transition of Patient and Testing Services duties.
- Review the vesting schedule of Mr. Johnson's outstanding equity awards during the consulting term.
- Monitor for any future announcements regarding the appointment of a permanent replacement for the President of Patient and Testing Services.